Microsoft initially blamed a traffic surge in part of its infrastructure and an issue with a component that processes server health. It cited "elevated load across multiple regions," caused by servers being unexpectedly unavailable, with some failing automated health checks. Microsoft said it has …
The company said the timing reflects assay refinement timelines and ongoing dialogue with the FDA, and that the plan depends on the outcome of that dialogue. Market data show the submission had previously been targeted for the fourth quarter of 2026.
Revenue fell to $4.2 million from $9.6 million a year earlier, below market estimates of about $7.8 million. The net loss widened to $87.7 million, or $0.68 per share, from $60.0 million, and market estimates had pointed to a loss per share of roughly …
Management said third quarter revenue was below its expectations. It pointed to several of its largest accounts, citing isolated account-level issues and field organization changes that caused more disruption than anticipated, and said scheduled fourth quarter cases have begun to recover.
The company said the pre-specified 80th event has occurred in REGAL and that the final analysis is underway. It expects to report topline primary endpoint results this month, narrowing the fourth-quarter timeframe given earlier. No efficacy data from the trial has been disclosed.
The offering covers 15,000,000 shares at $10.00 each, about 17.5% below the prior close, for expected gross proceeds of $150 million beforeUnderwritingdiscounts and expenses. All of the shares are being sold by the company, and the underwriters have a 30-day option to buy up …
The operating loss narrowed to $6.8 million from $7.6 million, and the net loss was $6.6 million, or $0.15 per share, versus $7.3 million, or $0.16 per share. An organizational realignment is on track to reach a full run rate of about $1.75 million …
Net income was R$276 million, up 31% from a year ago and 38% from the second quarter. AnnualizedReturn on Equityreached 22.4%, and the efficiency ratio improved 470 basis points to 44.2% as net interest income plus fees grew 9% while operating expenses stayed flat.
Third quarter gross sales were $591 million, or $1.5 billion year to date, and quarterly EBITDA was in line with last year. Fertilizers drove the growth, with urea realized prices at $561 per tonne, up $81. Fertilizer EBITDA was $109 million in the third …
Full-year 2026 guidance of $650 million to $700 million in revenue and $180 million to $220 million in adjusted EBITDA is now expected at the lower end. Hitting the low end requires roughly $327 million of fourth quarter revenue. Management said the fourth quarter …